SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics (“Silverback”), a biopharmaceutical company advancing a pipeline of therapies that are systemically delivered, but locally active, today announced the appointment of Vickie L. Capps as director and audit committee chair.
“Vickie has had a distinguished career in finance and executive leadership, and I was fortunate to have her guidance on the board of Synthorx,” said Laura Shawver, Ph.D., president, chief executive officer and director of Silverback Therapeutics. “Her exceptionally strong skill set as a senior finance and audit professional, in addition to strategic business development and corporate governance acumen, will be critical as Silverback advances to a clinical stage company later this year.”
In addition to Silverback, Ms. Capps is a member of the board of directors and the audit committee chair of each of NuVasive, Inc., a public medical device company (Nasdaq:NUVA) and Otonomy, Inc., a public biopharmaceutical company (Nasdaq:OTIC). She is a member of the board of directors of Amedisys, Inc., a public home health and hospice company (Nasdaq:AMED), and a member of its audit and compensation committees. Ms. Capps is also a member of the boards of directors of OmniGuide, Inc., a private medical device company, and the San Diego State University Research Foundation. Ms. Capps is a member of the Senior Advisory Board of Consonance Capital Partners, a healthcare focused private equity firm. She previously served as a member of the boards of directors of several other public and private companies, most recently, Synthorx, Inc. (Nasdaq), prior to its sale to Sanofi in January 2020, and Enclara Pharmacia (private) prior to its sale to Humana in January 2020. Ms. Capps is a Certified Public Accountant and she received her Bachelor of Science degree in business administration and accounting from San Diego State University.
About Silverback Therapeutics™
Silverback Therapeutics is a privately held biopharmaceutical company advancing a pipeline of therapies that are systemically delivered, but locally active and target fundamental disease pathways. Silverback’s ImmunoTAC™ technology is a targeted therapy platform designed to promote local modulation of important biologic pathways which enables innovative therapeutic approaches for oncology, virology, and fibrosis. Silverback’s lead candidate, SBT6050, is a novel immuno-oncology therapeutic comprised of a TLR8 specific agonist (a potent activator of myeloid cells) conjugated to a HER2-directed monoclonal antibody. Solid tumors, including those resistant to T cell targeted immunotherapy, are replete with myeloid cells. Activation and reprogramming of myeloid cells drives an innate immune response resulting in direct tumor killing and can also nucleate a T cell response. Successful activation of myeloid cells can lead to anti-tumor immunity, even in tumors that are resistant to immune checkpoint blockade. Clinical investigation of SBT6050 is expected to begin in 2H 2020. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com.